Company / R&D Expense
Illumina, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$967.0M
FY2025
5-year range
$682.0M / $1.4B
FY2021-FY2025
Trend
-17.3%
vs FY2024
Sector context
#11 of 110
Health Care
What the data says
Among 110 Health Care companies, Illumina, Inc. is in the top 10% for r&d expense. R&D Expense has fluctuated over the past 10 years, ranging from $401M in FY2017 to $1.4B in FY2023.
Based on SEC 10-K filings.
$967M in FY2025 with a 5-year CAGR of +7.2%. Top quartile in the Health Care sector.
Declined from $1.4B to $967M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +12.3%
- 5-Year CAGR
- +7.2%
- 10-Year CAGR
- -
Sector benchmark
Top 10% in Health CareTop 10% of 110This company $967.0M Sector average $298.2M
▼
+224.3% above sector average
Key checks
Key Insights
- 5-year CAGR of +7.2%, indicating consistent growth.
- In FY2025, r&d expense decreased 17.3% year-over-year.
- Ranks #11 out of 110 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2023.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
- Strong return on equity: 29.5%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $967.0M | -17.3% |
| FY2024 | $1.2B | -13.7% |
| FY2023 | $1.4B | +98.5% |
| FY2022 | $682.0M | -42.4% |
| FY2021 | $1.2B | +73.8% |
| FY2020 | $682.0M | +24.9% |
| FY2019 | $546.0M | +8.3% |
| FY2018 | $504.0M | +25.7% |
| FY2017 | $401.0M | -20.4% |
| FY2016 | $504.0M | +25.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026